Opzelura vs Tacrolimus vs Corticosteroids: Full Topical Comparison

When a dermatologist discusses topical vitiligo treatment, the conversation will land on one of three classes: JAK inhibitors (primarily Opzelura/ruxolitinib cream), calcineurin inhibitors (tacrolimus ointment, pimecrolimus cream), or corticosteroids. Each class has a distinct mechanism, distinct evidence base, distinct side effects, and appropriate clinical uses. Understanding how they compare helps patients participate meaningfully in treatment decisions.

The three classes at a glance

Opzelura (ruxolitinib cream 1.5%): JAK1/2 inhibitor. FDA-approved for non-segmental vitiligo in patients 12+. Most recently approved, strongest regulatory evidence, highest cost.

Tacrolimus ointment (Protopic): Calcineurin inhibitor. FDA-approved for atopic dermatitis; used off-label for vitiligo with extensive clinical experience over 20+ years. Moderate evidence, widely available, moderate cost.

Topical corticosteroids: Non-specific anti-inflammatory and immunosuppressive. No FDA approval specifically for vitiligo; used off-label. Variable evidence, widely available, low cost. Multiple potency classes.

Mechanism comparison

Opzelura: Blocks JAK1 and JAK2, directly interrupting the interferon-gamma signalling pathway that drives melanocyte destruction in vitiligo. Targeted mechanism — precisely addresses the key autoimmune pathway.

Tacrolimus: Inhibits calcineurin, which is required for T cell activation. Reduces the ability of cytotoxic T cells to activate and attack melanocytes. Less precisely targeted than JAK inhibition but effective at reducing local immune pressure.

Corticosteroids: Broadly suppresses inflammation and immune activity through glucocorticoid receptor activation. Reduces a wide range of inflammatory signals. Not specific to the vitiligo mechanism, which explains why long-term use often fails to maintain response.

Evidence comparison

Opzelura: Phase 3 randomised controlled trials (TRuE-V1 and TRuE-V2) with 52-week data. Clear, well-controlled evidence. Approximately 30% of patients achieve ≥75% facial repigmentation at one year. Regulatory standard evidence.

Tacrolimus: Extensive body of open-label and small controlled studies over 20+ years. No large phase 3 RCT specifically for vitiligo. Meta-analyses consistently show efficacy for facial vitiligo. Evidence is real but lower quality than Opzelura.

Corticosteroids: Evidence from small, heterogeneous studies. May halt active spread in the short term; repigmentation data is weaker than for calcineurin inhibitors. Long-term efficacy is limited by side effects that restrict use.

Side effect comparison

Opzelura:

Local application-site reactions (itch, redness) in a small percentage
Class-wide JAK inhibitor warnings (serious infections, thrombosis, malignancy) — based on systemic JAK inhibitors; topical absorption is significantly lower
Not recommended in pregnancy or breastfeeding
Safe for sensitive facial skin; no atrophy risk

Tacrolimus:

Burning/stinging on initial application (diminishes over weeks)
Black box warning for theoretical cancer risk (based on systemic calcineurin inhibitors in immunocompromised patients — widely considered overstated for topical use at standard doses)
Does not cause skin atrophy
Safe for sensitive areas including around eyes, lips

Corticosteroids:

Skin atrophy: The major long-term concern — corticosteroids thin the skin, cause telangiectasias and striae with prolonged use
Intraocular pressure elevation: Particularly with periorbital use — risk of steroid-induced glaucoma
Cataracts: With periocular use
HPA axis suppression: With extensive use or high-potency formulations
Steroid-induced acne and folliculitis
These risks limit corticosteroids to short-term use, particularly on the face

Appropriate clinical uses

When Opzelura is the first choice

Adult or adolescent patients (12+) with facial or body vitiligo
Access to insurance coverage or patient assistance program
When the strongest evidence base is the priority
For body vitiligo where tacrolimus has weaker evidence
Combination with phototherapy for best outcomes

When tacrolimus is the first choice

Cost or insurance access precludes Opzelura
Children under 12 (Opzelura not approved; tacrolimus 0.03% is)
Eyelid and periorbital use (where corticosteroids are specifically avoided)
Patients in pregnancy or breastfeeding where off-label tacrolimus may be preferable to the newer JAK inhibitor
Patients with both vitiligo and atopic eczema where a single agent addresses both

When corticosteroids are used

Short-course treatment to halt active, rapidly spreading vitiligo
Body areas where skin atrophy risk is lower (trunk, extremities with appropriate monitoring)
Combination with phototherapy for brief periods under medical supervision
Not for face, eyelids, groin, or axillae long-term

When none of these is adequate

When topicals alone are insufficient — particularly for body vitiligo that does not respond to facial-level results — combining any of the above with narrowband UVB phototherapy significantly improves outcomes. The Opzelura and NbUVB combination has the strongest recent evidence.

Cost comparison

Treatment	Cost (US, without coverage)
Generic corticosteroid cream	$10–30/tube
Generic tacrolimus 0.1% 60g	$50–150/tube
Opzelura 60g	$2,000+/tube (list price)

Cost is the single most common reason patients use tacrolimus or corticosteroids rather than Opzelura, regardless of which is clinically preferred. Opzelura’s manufacturer offers patient assistance programs; insurance coverage is improving but requires prior authorisation.

The complete head-to-head

Feature	Opzelura	Tacrolimus	Corticosteroids
FDA approval for vitiligo	Yes	No (off-label)	No (off-label)
Evidence quality	Phase 3 RCT	Multiple small studies	Small studies
Body efficacy	Strong	Moderate	Weak long-term
Face efficacy	Strongest available	Strong	Moderate short-term
Skin atrophy risk	None	None	Yes (long-term)
Eye safety	Caution near eyes	Safe periorbital	Avoid near eyes
Age restriction	12+	2+ (0.03%)	No restriction
Cost	Very high	Moderate	Low
Availability	Specialty pharmacy	Widely available	Ubiquitous

The tacrolimus vs Opzelura guide provides a deeper comparison of just those two agents. The vitiligo treatment options comparison gives the full landscape including phototherapy and systemic options.